Maertens Ophélia, Brems Hilde, Vandesompele Jo, De Raedt Thomas, Heyns Ine, Rosenbaum Thorsten, De Schepper Sofie, De Paepe Anne, Mortier Geert, Janssens Sandra, Speleman Frank, Legius Eric, Messiaen Ludwine
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
Hum Mutat. 2006 Oct;27(10):1030-40. doi: 10.1002/humu.20389.
Neurofibromatosis type 1 (NF1) is mainly characterized by the occurrence of benign peripheral nerve sheath tumors or neurofibromas. Thorough investigation of the somatic mutation spectrum has thus far been hampered by the large size of the NF1 gene and the considerable proportion of NF1 heterozygous cells within the tumors. We developed an improved somatic mutation detection strategy on cultured Schwann cells derived from neurofibromas and investigated 38 tumors from nine NF1 patients. Twenty-nine somatic NF1 lesions were detected which represents the highest NF1 somatic mutation detection rate described so far (76%). Furthermore, our data strongly suggest that the acquired second hit underlies reduced NF1 expression in Schwann cell cultures. Together, these data clearly illustrate that two inactivating NF1 mutations, in a subpopulation of the Schwann cells, are required for neurofibroma formation in NF1 tumorigenesis. The observed somatic mutation spectrum shows that intragenic NF1 mutations (26/29) are most prevalent, particularly frameshift mutations (12/29, 41%). We hypothesize that this mutation signature might reflect slightly reduced DNA repair efficiency as a trigger for NF1 somatic inactivation preceding tumorigenesis. Joint analysis of the current and previously published NF1 mutation data revealed a significant difference in the somatic mutation spectrum in patients with a NF1 microdeletion vs. non-microdeletion patients with respect to the prevalence of loss of heterozygosity events (0/15 vs. 41/81). Differences in somatic inactivation mechanism might therefore exist between NF1 microdeletion patients and the general NF1 population.
1型神经纤维瘤病(NF1)主要特征为良性周围神经鞘瘤或神经纤维瘤的发生。迄今为止,由于NF1基因规模庞大且肿瘤内NF1杂合细胞比例相当可观,对体细胞突变谱的全面研究受到了阻碍。我们针对源自神经纤维瘤的培养雪旺细胞开发了一种改进的体细胞突变检测策略,并对9例NF1患者的38个肿瘤进行了研究。检测到29个体细胞NF1病变,这代表了迄今为止报道的最高NF1体细胞突变检测率(76%)。此外,我们的数据强烈表明,获得性二次打击是雪旺细胞培养中NF1表达降低的基础。总之,这些数据清楚地表明,在雪旺细胞亚群中发生两个失活的NF1突变是NF1肿瘤发生过程中神经纤维瘤形成所必需的。观察到的体细胞突变谱显示,基因内NF1突变(26/29)最为普遍,尤其是移码突变(12/29,41%)。我们推测,这种突变特征可能反映了DNA修复效率略有降低,这是肿瘤发生前NF1体细胞失活的触发因素。对当前及先前发表的NF1突变数据进行联合分析发现,NF1微缺失患者与非微缺失患者在体细胞突变谱方面存在显著差异,即杂合性缺失事件的发生率不同(0/15 vs. 41/81)。因此,NF1微缺失患者与一般NF1人群之间可能存在体细胞失活机制的差异。